eye disease
-
Startup Tenpoint Lands $70M to Bring Vision-Restoring Cell Therapy to the Eye
Tenpoint Therapeutics’ name refers to the time it takes for an image to hit the retina and be processed by the brain. The regenerative medicine startup is developing cell therapies it hopes restore that vision capability for patients with degenerative eye disorders.
-
EyePoint Pharma Sells U.S. Rights to Eye Med to Become Pure Play Drug Developer
By selling U.S. rights to Yutiq, EyePoint Pharmaceuticals gets $75 million cash to support its drug pipeline. The company’s lead product candidate is in mid-stage development for wet age-related macular degeneration and non-proliferative diabetic retinopathy.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Viatris Sees Vision Drugs as Key to Growth and Commits $750M to Two M&A Deals
Two years after the close of the merger that formed Viatris, the company is acquiring Oyster Point Pharma and Famy Life Sciences to expand its scope in ophthalmology, one of three therapeutic areas it is now focusing on for revenue growth.
-
Sea creature-inspired biotech Ascidian surfaces with $50M and a new way to edit RNA
Ascidian Therapeutics is developing therapies for inherited disorders that work by editing RNA with an approach that could offer advantages over currently available genetic medicines. The biotech’s lead program is in preclinical development for Stargardt disease, a rare eye disorder caused by multiple genetic mutations.
-
Alcon ups its glaucoma game again with $770M Aerie Pharma acquisition
The Aerie Pharma acquisition brings Alcon two commercialized glaucoma products, as well as a pipeline of programs in various stages of development for other eye diseases. Alcon has been an active dealmaker, turning to M&A as a way to bolster its eye products portfolio and pipeline.
-
MedCity Influencers, BioPharma
Current advancements in wet AMD are not enough
AMD in particular impacts as many as 11 million Americans. About 15% of those affected have neovascular or wet AMD. It’s a devastating disease that can lead to irreversible vision loss.
-
Devices & Diagnostics, Health Services
Two firms team up to facilitate at-home screenings to prevent blindness
MedArrive providers will use Spect’s artificial intelligence-enabled telemedicine platform to screen patients at home for eye diseases such as diabetic retinopathy, glaucoma and age-related macular degeneration.
Promoted
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
